Home › Funds › Two Sigma Investments › RXRX
Two Sigma Investments position in RXRX
RECURSION PHARMACEUTICALS IN · Health Care
Latest position (Q2 2026)3.35M sh
Reported value held$12.31M
Portfolio Weight0.01%
First reportedQ1 2022
Last changeReduce
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2022 | 200.13K | $1.43M | New |
| Q4 2022 | 73.10K | $563.62K | New |
| Q1 2023 | 208.14K | $1.39M | Add |
| Q3 2023 | 392.32K | $3.00M | New |
| Q4 2023 | 532.64K | $5.25M | Add |
| Q1 2024 | 896.48K | $8.94M | Add |
| Q2 2024 | 1.43M | $10.70M | Add |
| Q3 2024 | 1.60M | $10.53M | Add |
| Q4 2024 | 1.66M | $11.23M | Add |
| Q1 2025 | 1.15M | $6.10M | Reduce |
| Q2 2025 | 1.17M | $5.91M | Add |
| Q3 2025 | 2.45M | $11.96M | Add |
| Q4 2025 | 3.08M | $12.58M | Add |
| Q1 2026 | 4.07M | $12.48M | Add |
| Q2 2026 | 3.35M | $12.31M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding RXRX
- Vanguard Group 47.19M sh · $193.00M · Q4 2025
- BlackRock Inc 50.30M sh · $184.62M · Q2 2026
- ARK Invest 41.34M sh · $151.71M · Q2 2026
- Baillie Gifford & Co 23.49M sh · $86.20M · Q2 2026
- Geode Capital Management 13.82M sh · $50.72M · Q2 2026
- UBS Group AG 8.95M sh · $32.84M · Q2 2026
- Norges Bank Investment Management 6.83M sh · $25.08M · Q2 2026
- Northern Trust Corp 4.76M sh · $17.46M · Q2 2026
- Marshall Wace 4.71M sh · $17.30M · Q2 2026
- Charles Schwab Investment Management 4.14M sh · $15.19M · Q2 2026
- Goldman Sachs Group 3.92M sh · $14.38M · Q2 2026